KUKJEON PHARMACEUTICAL Co., Ltd (KOSDAQ:307750)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,715.00
-105.00 (-2.75%)
At close: Apr 9, 2026

KUKJEON PHARMACEUTICAL Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
131,039136,468121,998103,71185,354
Other Revenue
-0-0---0
131,039136,468121,998103,71185,354
Revenue Growth (YoY)
-3.98%11.86%17.63%21.51%-
Cost of Revenue
112,573114,59496,72184,19567,409
Gross Profit
18,46621,87425,27719,51517,946
Selling, General & Admin
14,49515,32712,81711,4518,699
Research & Development
3,6324,6844,8213,9812,651
Amortization of Goodwill & Intangibles
118.43114.1389.870.340.61
Operating Expenses
21,03021,50718,76816,02711,836
Operating Income
-2,564366.716,5093,4886,109
Interest Expense
-5,159-8,220-5,735-1,802-284.47
Interest & Investment Income
38.76878.981,5911,037208.91
Earnings From Equity Investments
-74.07-57.481.15301.09-
Currency Exchange Gain (Loss)
368.55-1,655-253.67-1,215-869.65
Other Non Operating Income (Expenses)
2,44310,498-391.289,279196.4
EBT Excluding Unusual Items
-4,9461,8111,72211,0895,360
Gain (Loss) on Sale of Investments
285.191,83116.2867.84-275.98
Gain (Loss) on Sale of Assets
-25.3-57.43--69.18-0
Other Unusual Items
-977.97-2,706---
Pretax Income
-5,665879.321,73811,0885,084
Income Tax Expense
-844.24341.65-2,9542,2101,046
Earnings From Continuing Operations
-4,820537.674,6928,8774,038
Minority Interest in Earnings
521.441,19913270.7-
Net Income
-4,2991,7364,8248,9484,038
Net Income to Common
-4,2991,7364,8248,9484,038
Net Income Growth
--64.01%-46.09%121.59%-
Shares Outstanding (Basic)
5050494944
Shares Outstanding (Diluted)
5050495144
Shares Change (YoY)
0.77%1.09%-4.23%16.16%-
EPS (Basic)
-86.0035.0098.31182.3591.54
EPS (Diluted)
-86.0035.0098.3111.3591.00
EPS Growth
--64.40%766.11%-87.53%-
Free Cash Flow
7,4942,100-44,269-29,304-7,367
Free Cash Flow Per Share
149.9242.33-902.17-571.94-167.01
Gross Margin
14.09%16.03%20.72%18.82%21.02%
Operating Margin
-1.96%0.27%5.33%3.36%7.16%
Profit Margin
-3.28%1.27%3.95%8.63%4.73%
Free Cash Flow Margin
5.72%1.54%-36.29%-28.26%-8.63%
EBITDA
2,6635,4729,6434,9327,215
EBITDA Margin
2.03%4.01%7.90%4.75%8.45%
D&A For EBITDA
5,2275,1053,1341,4441,106
EBIT
-2,564366.716,5093,4886,109
EBIT Margin
-1.96%0.27%5.33%3.36%7.16%
Effective Tax Rate
-38.85%-19.94%20.58%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.